This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

This study has been completed.
23andMe, Inc.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: May 9, 2012
Last updated: May 7, 2015
Last verified: May 2015
This pilot, non-interventional, observational, Web-based, prospective cohort study is designed to collect self-reported safety and effectiveness and genetic data from subjects with locally recurrent breast cancer (BC) or metastatic breast cancer (MBC), metastatic colorectal cancer (MCRC), metastatic non-squamous non-small cell lung cancer (MNSCLC), recurrent glioblastoma (RGBM), or metastatic renal cell cancer (MRCC) in the United States who have been previously treated with Avastin (bevacizumab). The cohort will be composed of male and female subjects who have been diagnosed with locally recurrent BC or MBC, MCRC, MNSCLC, RGBM, or MRCC who have received treatment with bevacizumab in combination with chemotherapy, which started prior to or up to 31 December 2012. Participants will be self-referred to this study. They will be recruited online via a number of sources, including through the involvement of patient advocacy groups, social media tools, traditional media, physicians, and events to raise awareness of this study. After appropriate informed consent and authorization are obtained, data will be collected directly from subjects in an online survey. Participants will be contacted electronically to complete quarterly follow-up surveys. The follow-up period will be 1 year from responding to the baseline survey. DNA collection will be performed as part of this study. DNA will be extracted from saliva, which will be provided by the subject utilizing a collection kit sent to the participants for at-home use.

Breast Cancer Colorectal Cancer Non-Small Cell Lung Cancer Glioblastoma Renal Cell Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Percentage of subjects who complete the survey and who provide evaluable genetic information (DNA) [ Time Frame: 24 months ]

Secondary Outcome Measures:
  • Clinical characteristics (current disease status/previous treatments) of subjects participating in this study [ Time Frame: 24 months ]
  • Demographic distribution (age, sex) of subjects participating in this study [ Time Frame: 24 months ]

Biospecimen Retention:   Samples With DNA
saliva, optional blood

Enrollment: 276
Study Start Date: March 2012
Study Completion Date: November 2014
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Participants with history of metastatic or locally recurrent breast cancer treated with Avastin

Inclusion Criteria:

  • Locally recurrent BC or MBC, MCRC, MNSCLC, RGBM, or MRCC in patients treated or on treatment with bevacizumab, which started prior to or up to 31 December 2012
  • Ability to read and understand English
  • Ability to access and use a computer connected to the Internet
  • Signed informed consent and authorization form
  • Residence in the United States
  • At least 18 years of age

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01598597

  Hide Study Locations
United States, Alabama
Many locations, Alabama, United States
United States, Alaska
Many locations, Alaska, United States
United States, Arizona
Many locations, Arizona, United States
United States, Arkansas
Many locations, Arkansas, United States
United States, California
Many locations, California, United States
United States, Colorado
Many locations, Colorado, United States
United States, Connecticut
Many locations, Connecticut, United States
United States, Delaware
Many locations, Delaware, United States
United States, Florida
Many locations, Florida, United States
United States, Georgia
Many locations, Georgia, United States
United States, Hawaii
Many locations, Hawaii, United States
United States, Idaho
Many locations, Idaho, United States
United States, Illinois
Many locations, Illinois, United States
United States, Indiana
Many locations, Indiana, United States
United States, Iowa
Many locations, Iowa, United States
United States, Kansas
Many locations, Kansas, United States
United States, Kentucky
Many locations, Kentucky, United States
United States, Louisiana
Many locations, Louisiana, United States
United States, Maine
Many locations, Maine, United States
United States, Maryland
Many locations, Maryland, United States
United States, Massachusetts
Many locations, Massachusetts, United States
United States, Michigan
Many locations, Michigan, United States
United States, Minnesota
Many locations, Minnesota, United States
United States, Mississippi
Many locations, Mississippi, United States
United States, Missouri
Many locations, Missouri, United States
United States, Montana
Many locations, Montana, United States
United States, Nebraska
Many locations, Nebraska, United States
United States, Nevada
Many locations, Nevada, United States
United States, New Hampshire
Many locations, New Hampshire, United States
United States, New Jersey
Many locations, New Jersey, United States
United States, New Mexico
Many locations, New Mexico, United States
United States, New York
Many locations, New York, United States
United States, North Carolina
Many locations, North Carolina, United States
United States, North Dakota
Many locations, North Dakota, United States
United States, Ohio
Many locations, Ohio, United States
United States, Oklahoma
Many locations, Oklahoma, United States
United States, Oregon
Many locations, Oregon, United States
United States, Pennsylvania
Many locations, Pennsylvania, United States
United States, Rhode Island
Many locations, Rhode Island, United States
United States, South Carolina
Many locations, South Carolina, United States
United States, South Dakota
Many locations, South Dakota, United States
United States, Tennessee
Many locations, Tennessee, United States
United States, Texas
Many locations, Texas, United States
United States, Utah
Many locations, Utah, United States
United States, Vermont
Many locations, Vermont, United States
United States, Virginia
Many locations, Virginia, United States
United States, Washington
Many locations, Washington, United States
United States, West Virginia
Many locations, West Virginia, United States
United States, Wisconsin
Many locations, Wisconsin, United States
United States, Wyoming
Many locations, Wyoming, United States
Sponsors and Collaborators
Genentech, Inc.
23andMe, Inc.
Study Director: Clinical Trials Genentech, Inc.
  More Information

Responsible Party: Genentech, Inc. Identifier: NCT01598597     History of Changes
Other Study ID Numbers: GO28289
Study First Received: May 9, 2012
Last Updated: May 7, 2015

Additional relevant MeSH terms:
Breast Neoplasms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Carcinoma, Renal Cell
Neoplasms by Site
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type processed this record on September 21, 2017